Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Is it too late to buy Avidity stock after Novartis deal?
10:22am, Monday, 27'th Oct 2025
Novartis (NYSE: NVS) revealed plans of acquiring Avidity Biosciences Inc (NASDAQ: RNA) in a $12 billion all-cash transaction – valuing each share of the biotech company at $72 on Monday. The announc
Novartis to acquire Avidity Biosciences in $12B deal
09:13am, Monday, 27'th Oct 2025
Novartis AG (ADR) (NYSE:NVS) announced it will acquire San Diego-based biopharmaceutical firm Avidity Biosciences (NASDAQ:RNA), which is developing RNA therapeutics for genetic neuromuscular diseases,
5 Things to Know Before the Stock Market Opens
09:05am, Monday, 27'th Oct 2025
Stock futures are pointing to a sharply higher open this morning after major indexes closed last week at record highs; investor sentiment is getting a boost after President Donald Trump said he was op
Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk
08:16am, Monday, 27'th Oct 2025
President Donald Trump penned several trade agreements ahead of his expected meeting with China leader Xi Jinping later this week. Novartis announced it will buy Avidity Biosciences.
Wall Street Breakfast Podcast: Novartis Puts $12B On The Table
06:54am, Monday, 27'th Oct 2025
Avidity Biosciences (RNA) surges 42% premarket after Novartis agrees to acquire the company for $12 billion, paying $72 per share in cash. The RNA deal signals renewed Big Pharma interest in RNA thera
Novartis shares slip, Avidity soars after $12 billion biotech deal
06:29am, Monday, 27'th Oct 2025
Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U.S. biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CE
Novartis Agrees $12 Billion Biotech Deal for Avidity
04:59am, Monday, 27'th Oct 2025
Novartis agreed to buy biotechnology company Avidity in a deal valued at $12 billion, making it the Swiss drugmaker's biggest acquisition in more than a decade and adding several potential blockbust
Novartis Agrees to Acquire Avidity Biosciences for $12 Billion
05:33pm, Sunday, 26'th Oct 2025
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
Novartis to acquire Avidity Biosciences for about $12B
03:46pm, Sunday, 26'th Oct 2025
Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx
Novartis Deal Values Avidity Biosciences At $12 Billion
03:29pm, Sunday, 26'th Oct 2025
The acquisition would raise the 2024-2029 expected sales compound annual growth rate for Novartis to 6% from 5%, it said.
Novartis to acquire Avidity Biosciences for $12 billion
01:07pm, Sunday, 26'th Oct 2025
Swiss drugmaker Novartis on Sunday said it agreed to acquire Avidity Biosciences for $12 billion.
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
01:07pm, Sunday, 26'th Oct 2025
Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the Novartis
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
12:26pm, Sunday, 26'th Oct 2025
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports
11:09am, Sunday, 26'th Oct 2025
Swiss drugmaker Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter.
